References
- Fossgreen J., Kirchheiner B., Petersen F. O., Tophoj E., Zachariae E. Clinical evaluation of ketoprofen (19 583 RP) in rheumatoid arthritis. Scand. J. Rheumatol. 1976, Suppl. 14: 93–981. Fossgreen J., Kirchheiner B., Petersen F. O., Tophoj E., Zachariae E. Clinical evaluation of ketoprofen (19 583 RP) in rheumatoid arthritis. Scand. J. Rheumatol. 1976, Suppl. 14: 93–98
- Goldie I. F. Piroxicam and naproxen in osteoarthritis. A clinical comparison. Am. J. Med. 1982; 72: 50–532. Goldie I. F. Piroxicam and naproxen in osteoarthritis. A clinical comparison. Am. J. Med. 1982; 72: 50–53
- Gyory A. N. Orudis in the management of rheumatoid arthritis and osteoarthrosis of the hip: comparison with indomethacin. Br. Med. J. 1972; 4: 398–4003. Gyory A. N. Orudis in the management of rheumatoid arthritis and osteoarthrosis of the hip: comparison with indomethacin. Br. Med. J. 1972; 4: 398–400
- Lacasse Y., Caille G. Pharmacokinetic profile of four formulations of ketoprofen. Internal report, Rhone-Poulenc. 19824. Lacasse Y., Caille G. Pharmacokinetic profile of four formulations of ketoprofen. Internal report, Rhone-Poulenc. 1982
- Mills S. B., Bloch M., Bruckner F. E. Double-blind crossover study of ketoprofen and ibuprofen in the management of rheumatoid arthritis. Br. Med. J. 1973; 4: 82–845. Mills S. B., Bloch M., Bruckner F. E. Double-blind crossover study of ketoprofen and ibuprofen in the management of rheumatoid arthritis. Br. Med. J. 1973; 4: 82–84
- Ranløv P. J., Pors Nielsen S., Bärenholdt O. Faecal blood loss during administration of acetylsalicylic acid, ketoprofen and two new ketoprofen sustained-release compounds. Scand. J. Rheumatol. 1983; 12: 280–2846. Ranløv P. J., Pors Nielsen S., Bärenholdt O. Faecal blood loss during administration of acetylsalicylic acid, ketoprofen and two new ketoprofen sustained-release compounds. Scand. J. Rheumatol. 1983; 12: 280–284
- Ruotsalainen P., Ahonen M. A double-blind crossover trial of 200 mg slow-release ketoprofen (Orudis Depot) versus 20 mg piroxicam (Feldene) in the symptomatic treatment of rheumatoid arthritis. 1983, Internal report, Rhône-Poulenc.7. Ruotsalainen P., Ahonen M. A double-blind crossover trial of 200 mg slow-release ketoprofen (Orudis Depot) versus 20 mg piroxicam (Feldene) in the symptomatic treatment of rheumatoid arthritis. 1983, Internal report, Rhône-Poulenc.
- Steger W. Vergleichende klinische Untersuchung zur Wirksamkeit und Verträglichkeit von Orudis Retard (200 mg 'slow-release' ketoprofen) versus Orudis (50 mg ketoprofen). 1982, Internal report, Rhône-Poulenc.8. Steger W. Vergleichende klinische Untersuchung zur Wirksamkeit und Verträglichkeit von Orudis Retard (200 mg 'slow-release' ketoprofen) versus Orudis (50 mg ketoprofen). 1982, Internal report, Rhône-Poulenc.
- Zutschi D. W., Stern D., Bloch M., Mason R. M. Ketoprofen: double-blind crossover study with indomethacin in patients with rheumatoid arthritis. Rheumatol. Rehabil. 1974; 13: 10–169. Zutschi D. W., Stern D., Bloch M., Mason R. M. Ketoprofen: double-blind crossover study with indomethacin in patients with rheumatoid arthritis. Rheumatol. Rehabil. 1974; 13: 10–16